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ABSTRACT
High Mobility Group A1 (HMGA1) is an architectural chromatin factor that 
promotes neoplastic transformation and progression. However, the mechanism by 
which HMGA1 exerts its oncogenic function is not fully understood. Here, we show 
that cyclin E2 (CCNE2) acts downstream of HMGA1 to regulate the motility and 
invasiveness of basal-like breast cancer cells by promoting the nuclear localization and 
activity of YAP, the downstream mediator of the Hippo pathway. Mechanistically, the 
activity of MST1/2 and LATS1/2, the core kinases of the Hippo pathway, are required 
for the HMGA1- and CCNE2-mediated regulation of YAP localization. In breast cancer 
patients, high levels of HMGA1 and CCNE2 expression are associated with the YAP/
TAZ signature, supporting this connection. Moreover, we provide evidence that CDK 
inhibitors induce the translocation of YAP from the nucleus to the cytoplasm, resulting 
in a decrease in its activity. These findings reveal an association between HMGA1 
and the Hippo pathway that is relevant to stem cell biology, tissue homeostasis, and 
cancer.
INTRODUCTION
Breast cancer is a complex and multistep disease 
involving the accumulation of both molecular and 
morphological changes within a cell. A critical step in the 
clinical outcome of breast cancer is the metastatic spread 
of cancer cells [1]. Understanding the molecular basis 
of metastasis is crucial for elucidating the mechanisms 
underlying this disease and designing an appropriate 
treatment. 
The High Mobility Group A1 (HMGA1) gene 
encodes two proteins, HMGA1a and HMGA1b, which 
are generated via alternative splicing. Several studies 
have reported that HMGA1 expression is elevated in 
a variety of human cancers, including breast cancer, 
and enhanced HMGA1 protein expression has been 
associated with cancer metastasis [2-7]. Moreover, several 
reports have demonstrated a causal role of HMGA1 in 
inducing a transformed phenotype in cultured cells and 
in forming aggressive tumors in transgenic mice [8-
10]. The oncogenic activities of HMGA1 are essentially 
due to its ability to modulate chromatin structure by 
preferentially binding to AT-rich DNA regions and to 
form stereospecific, multiple complexes defined as 
“enhanceosomes” that regulate the expression of genes 
involved in tumor progression and metastasis [11-13].
Several results strongly support a specific role for 
CCNE2 in breast cancer. CCNE2 has been detected in 
various prognostic gene expression profiles that predict 
a shorter metastasis-free survival or relapse-free interval 
in breast cancer patients [14-16]. CCNE2 overexpression 
in breast cancer cells induces genomic instability but 
does not affect mitotic progression [17, 18]. Therefore, 
even though it appears that CCNE2 might play a role in 
cancer progression, its underlying molecular mechanism 
is unknown.
The Hippo signaling pathway is a novel growth 
control and tumor suppressor pathway consisting of a 
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kinase cascade comprising MST1/2 and LATS1/2 kinases 
[19-23]. Activation of the Hippo pathway results in the 
inactivation of YAP/TAZ proto-oncogenes via LATS1/2-
mediated direct phosphorylation [22, 24]. Whereas 
phosphorylated YAP is sequestered in the cytoplasm, 
dephosphorylated YAP accumulates in the nucleus and 
acts primarily via the TEAD family of transcription 
factors to promote cell proliferation and organ growth. 
In tumors, YAP and TAZ are involved in the epithelial-
to-mesenchymal transition (EMT), cancer stem cell 
properties, enhanced cell proliferation and acquisition of 
metastatic potential [25]. 
In this study, we investigated the contribution of 
HMGA1 and CCNE2 to breast cancer cell migration and 
invasion. Using basal-like breast cancer cell lines, we 
demonstrated that CCNE2 is an important downstream 
factor of HMGA1 that mediates tumor aggressiveness. 
We found that HMGA1 and CCNE2 exert their effect on 
cell migration by regulating YAP cellular localization and 
activity, through the action on the Hippo core kinases. 
Intriguingly, we found a clinically relevant relationship 
between HMGA1 and CCNE2 expression and the YAP/
TAZ signature in breast cancer patients. Moreover, we 
show that CDK inhibitors effectively modulate YAP 
activity. Thus, this study identifies a novel HMGA1-
CCNE2-YAP axis that regulates the metastasis of basal-
like breast cancer, suggesting that this pathway might 
serve as a potential target for cancer therapy.
RESULTS
HMGA1 regulates CCNE2 in breast cancer cell 
lines
We recently identified a 130 gene-signature that is 
regulated by HMGA1 in breast cancer. This gene-signature 
displays prognostic value for breast cancer and correlates 
with a more aggressive and highly invasive basal-like 
cancer subtype [5].
To gain insight into the correlation between the 
expression level of these genes and the clinical data 
concerning poor patient prognosis, we constructed 
corresponding Cox proportional hazards models using 
public datasets of breast cancer gene expression. CCNE2 
was among the genes that most highly correlated with 
poor clinical outcome and whose expression was tightly 
regulated by HMGA1 (Supplementary Figure S1a).
Next, we used basal-like breast cancer cell lines 
(MDA-MB-231 and MDA-MB-157) to assess whether 
CCNE2 expression is dependent on HMGA1 expression. 
Silencing of HMGA1 using a specific siRNA caused 
significant down-regulation of CCNE2 expression at both 
the mRNA and protein levels in the MDA-MB-231 and 
MDA-MB-157 breast cancer cell lines (Figure 1a and 
b). This effect was confirmed in MDA-MB-231 cells 
using a second independent siRNA against HMGA1 
(Supplementary Figure S1b and c). At the same time, the 
overexpression of a tagged form of HMGA1a in MDA-
MB-231 cells was able to up-regulate the expression of 
endogenous CCNE2 mRNA (Figure 1c). 
We then tested whether the CCNE2 gene could be 
directly regulated by HMGA1 overexpressing a tagged 
form of HMGA1a together with a luciferase reporter gene 
construct containing the promoter region of CCNE2 (from 
– 580 to + 226). The overexpression of HMGA1a was able 
to increase the activity of the promoter while a deletion 
mutant ΔCCNE2 (+1 to + 223) had a much lower basal 
activity and it was weakly induced by HMGA1a (Figure 
1d). Consistently, the silencing of endogenous HMGA1 
expression was able to decrease the promoter activity of 
the reporter gene (Supplementary Figure S1d). 
To further investigate whether CCNE2 is a direct 
target of HMGA1 in vivo, we performed chromatin 
immunoprecipitation (ChIP) assays in MDA-MB-231 
cells. In addition of testing the promoter region we 
assayed also two more upstream regions, because from 
an inspection to the 5’ flanking region of the CCNE2 
gene we observed that at -1.8 kb and at -8.6 kb there are 
two long regions of 3.0 kb and of 2.0 kb, that we named 
AT-rich region 1 (AT-RR1) and AT-rich region 2 (AT-
RR2), with an unusual AT-rich composition, 62% and 
55% respectively. A MatInspector analysis indicated the 
presence of several HMGA1 binding sites in these two 
regions and, in addition, the MAR-Wiz tool indicated 
in the more distant one (AT-RR2) a Scaffold/Matrix-
Attachment-Region (S/MAR) suggesting the implication 
of these two putative regulatory elements in the regulation 
of the CCNE2 gene (Supplementary Figure S1e). ChIP 
experiments indicate that HMGA1 binds to the promoter 
region and, intriguingly, even more to AT-RR1 and AT-
RR2 (Figure 1e), suggesting that HMGA1 could act 
through these two regulatory regions as well. Altogether 
therefore these results demonstrate that HMGA1 regulates 
CCNE2 expression by binding to the CCNE2 gene.
HMGA1 expression is associated with that of 
CCNE2 in breast cancer patients
Next, we investigated the possible relationship 
between HMGA1 and CCNE2 expression in breast cancer 
patients. Based on the analysis of a breast cancer meta-
dataset, we detected a strong correlation between the 
HMGA1 and CCNE2 expression levels (linear regression 
model, P < 10-15) (Supplementary Figure S2a). Then, 
we stratified breast cancer samples according to their 
relative expression levels of HMGA1 and CCNE2, 
obtaining a significant difference in patient distribution 
(Supplementary Figure S2b upper panel, chi-square, P 
< 10-15). A similar result was obtained using the TCGA 
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breast cancer dataset (Supplementary Figure S2b lower 
panel, chi-square, P < 10-8). Moreover, when we classified 
patients according to grade and molecular subtype, we 
found concurrently elevated expression of both CCNE2 
and HMGA1 in Grade 3 breast cancer and in the more 
aggressive breast cancer subtypes (luminal B and 
basal-like; Figure 2a and Supplementary Figure S2c). 
Interestingly, Kaplan-Meier survival analysis revealed that 
patients expressing high levels of both genes exhibited a 
significantly higher probability (P < 10-15) of developing 
distant metastasis than patients expressing low levels of 
both genes or patients in which only HMGA1 was highly 
expressed (Figure 2b). Furthermore, a high expression 
level of CCNE2 alone correlated with a poorer prognosis 
when HMGA1 expression levels were low. This finding 
suggests that CCNE2 serves as the effector molecule in 
the HMGA1-CCNE2 axis and that CCNE2 participates 
in conferring an aggressive phenotype to the tumor. 
Figure 1: HMGA1 regulates CCNE2 expression. a. CCNE2 mRNA expression was measured after 72 h of HMGA1 silencing 
(siHMGA1) in MDA-MB-231 and MDA-MB-157 cells using real-time RT-PCR. The level of CCNE2 expression in HMGA1 silenced cells 
was compared to that in cells transfected with control siRNA (siCTRL). GAPDH was used for normalization. The data are represented as 
the mean±SD (n = 3). See Supplementary Figure S1b for mRNA down-regulation of CCNE2 after HMGA1 silencing using siA1_1, which 
targets a different region of HMGA1 (n = 3). b. CCNE2 protein expression was analyzed after 72 h of HMGA1 silencing (siHMGA1) 
in MDA-MB-231 and MDA-MB-157 cells. A representative Western blot is shown. ß-actin was used as a loading control. See also 
Supplementary Figure S1c for protein down-regulation of CCNE2 after HMGA1 silencing using siA1_1. c. HMGA1 3’UTR, CDS and 
CCNE2 mRNA expression was measured after 30 h of GFP-HMGA1a overexpression in MDA-MB-231. 3’UTR amplification detects only 
endogenous HMGA1 while CDS amplification detects both endogenous and overexpressed HMGA1 mRNA because pEGFP-N1 HMGA1a 
vector contains only the HMGA1a coding sequence without 3’UTR. Levels of each mRNA were compared to that in cells transfected 
with control vector (GFP). GAPDH was used for normalization. The data are represented as the mean±SD (n = 3). d. HEK293 cells were 
transiently cotransfected with the luciferase reporter plasmid CCNE2 or ΔCCNE2 in combination with the expression plasmid pcDNA3HA 
or pcDNA3HA-HMGA1a. pRL-CMV Renilla luciferase expression vector was included to normalize for transfection efficiencies. Values 
are reported as relative luciferase activity comparing to cells transfected with the reporter vector CCNE2 and pcDNA3HA. The data are 
represented as the mean±SD (n > 5). Below the graph, Western blot of HA-HMGA1a. See Supplementary Figure S1d for luciferase assay 
on HEK293 silenced for HMGA1 and transfected with luciferase reporter plasmid CCNE2. e. Chromatin immunoprecipitation analysis of 
HMGA1 binding to CCNE2 promoter from MDA-MB-231 cells. Chromatin was immunoprecipitated with anti-HMGA1 antibody or rabbit 
purified IgG as negative control. Promoter occupancy was analyzed by real-time PCR amplifying three different region: AT-RR2 (from 
-8606 to -8469), AT-RR1 (from -2833 to -2714) and CCNE2 promoter (from -368 to -246) and calculated as percentage of input chromatin 
bound (n = 3). *P < 0.05, **P < 0.001***P < 0.001; two-tailed Student’s t-test.
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This finding may also imply that CCNE2 expression, 
as expected, may be regulated by other transcriptional 
regulators because there is a subset of patients who 
express high CCNE2 levels and low HMGA1 levels. 
Taken together, these data suggest that the HMGA1-
CCNE2 axis may mediate the oncogenic properties of 
breast cancer subtypes that are more undifferentiated and 
confer a poor prognosis. Kaplan-Meier survival analysis 
revealed that the expression of CCNE2 alone significantly 
correlated with clinical outcome in breast cancer patients 
(Supplementary Figure S2d). Moreover, a multivariate 
analysis of a cohort of 1131 breast cancer patients (a 
subset of our meta-dataset) revealed that a low expression 
level of CCNE2, as well as negative lymph node status, 
is a significant (P = 0.01) independent factor of good 
prognosis (Figure 2c). 
CCNE2 acts downstream of HMGA1 to regulate 
the motility of breast cancer cells
In breast cancer cells, HMGA1 is primarily involved 
in regulating cell motility and invasiveness [5, 6]; however, 
its downstream effectors are not well characterized. 
Therefore, we explored the functional relevance of 
CCNE2 in cell motility and invasiveness. Initially, we 
performed a wound-healing assay after CCNE2 silencing. 
Down-regulation of CCNE2 using two different siRNAs 
significantly reduced the 2D migration ability of both 
MDA-MB-231 and MDA-MB-157 cells (Figure 3a). To 
specifically analyze the migration component of CCNE2 
activity, we performed Boyden chamber assays and 
found that cell migration was significantly impaired in 
MDA-MB-231 and MDA-MB-157 cells (Figure 3b and 
Supplementary Figure S3a). Moreover, using Matrigel-
coated inserts, we clearly determined that the invasion 
Figure 2: CCNE2 expression correlates with HMGA1 expression in breast cancer and tumor aggressiveness. a. Mosaic 
plot showing the expression of HMGA1 and CCNE2 in breast cancer samples. The samples were stratified based on tumor grade and the 
expression of these two genes (higher or lower that the mean expression of the given gene in the meta-dataset). The table shows the number 
of samples for each category. b. Kaplan–Meier survival curves showing the relevance of CCNE2 and HMGA1 expression to clinical 
outcome, specifically DMFS. The patients were stratified based on the expression of these two genes. c. Multivariate analysis of CCNE2 
expression in a breast cancer meta-dataset. 
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properties of all cell lines were dramatically decreased by 
CCNE2 silencing (Figure 3c and Supplementary Figure 
S3b), suggesting a direct involvement of CCNE2 in 
metastasis. 
The data described above establish CCNE2 as a 
participant in breast cancer cell migration and invasion. 
Next, we sought to verify whether CCNE2 serves as a 
downstream effector of HMGA1-induced cell migration. 
Indeed, the reintroduction of CCNE2 expression using 
pcDNA3HA-CCNE2 rescued the migration of HMGA1-
silenced MDA-MB-231 cells to levels comparable to those 
of control cells (Figure 3d).
Next, we examined whether silencing of CCNE2 
affects breast cancer cell proliferation. CCNE2 silencing 
did not significantly alter the proliferation of MDA-
MB-231 or MDA-MB-157 cells (Supplementary Figure 
S4a). Moreover, cell cycle analysis revealed a slight 
accumulation of cells in the G0/G1 phase only in the 
MDA-MB-157 cell line (Supplementary Figure S4b).
Taken together, these results suggest that CCNE2 
plays a specific role in promoting cell migration and 
invasion in metastatic breast cancer cell lines downstream 
of HMGA1.
HMGA1 and CCNE2 regulate the nuclear 
localization and activity of YAP
Next, we examined the mechanism by which 
CCNE2 mediates cell migration and invasion. To address 
this issue, we explored whether alterations in CCNE2 
expression correlate with RNA levels and protein 
phosphorylation levels by analyzing a cohort of 408 
breast cancer patient samples via RNA-seq and phospho-
proteomics approaches. Specifically, we categorized 
patients according to their CCNE2 expression levels and 
ranked the differential changes obtained from reverse 
phase protein array (RPPA) analysis. Among the most 
significant differential phosphorylations, we found 
an inverse relationship between CCNE2 expression 
and the phosphorylation of YAP at Ser127 (Figure 
4a). Phosphorylation of YAP at Ser127 induces YAP 
translocation from the nucleus to the cytoplasm, repressing 
its activity [22]. 
Thus, we hypothesized that HMGA1 and CCNE2 
participate in breast cancer cell migration via YAP by 
interfering with YAP phosphorylation at Ser127 and 
promoting its nuclear localization. Therefore, we silenced 
HMGA1 and CCNE2 in MDA-MB-231 and MDA-
MB-157 cells and we evaluated YAP localization via 
immunofluorescence analysis. As shown in Figure 4b and 
Supplementary Figure S5a and b, in the HMGA1- and 
CCNE2-silenced cells, YAP predominantly displayed 
a cytoplasmic cell distribution, losing its nuclear 
localization. 
To further support our hypothesis, the 
phosphorylation status of YAP at Ser127 was measured 
using a specific antibody in MDA-MB-231 cells in which 
CCNE2 and HMGA1 were silenced. As shown in Figure 
4c, silencing both HMGA1 and CCNE2 in MDA-MB-231 
cells increased the phosphorylation levels of YAP at 
Ser127. This result suggests that this modification may be 
responsible for the observed cytoplasmic relocalization 
of YAP and confirms in an in vitro model the inverse 
correlation between CCNE2 expression and YAP Ser127 
phosphorylation that was found in the tumor samples.
Furthermore, we monitored the effect of CCNE2 
and HMGA1 knockdown on well-established endogenous 
YAP target genes, such as BIRC5, CYR61 and CTGF. We 
found that CTGF and CYR61 were significantly down-
regulated upon HMGA1 and CCNE2 silencing, whereas 
BIRC5 appeared to be down-regulated, although this result 
was not significant (Figure 4d). Therefore, these results 
demonstrate that both CCNE2 and HMGA1 regulate 
the YAP target gene expression pattern. This important 
association was confirmed in breast cancer patients 
(TCGA breast cancer dataset). In fact, the differential 
activation of the YAP/TAZ signature is associated with the 
expression levels of both the CCNE2 and HMGA1 genes 
(Figure 4e, Chi-square, P < 10-15).
HMGA1 and CCNE2 regulate YAP through 
MST1/2 and LATS1/2 kinases
MST1/2 and LATS1/2 constitute the Hippo core 
kinase cassette and are the primary kinases responsible for 
YAP/TAZ phosphorylation and inactivation [22, 24], we 
therefore asked whether these kinases mediate the effect 
of HMGA1 and CCNE2 on YAP nuclear localization. 
Silencing of LATS1/2 and MST1/2 in MDA-MB-231 
cells almost completely rescued the effect of HMGA1 and 
CCNE2 depletion on YAP nuclear localization (Figure 5a). 
The rescue on nuclear localization following LATS1/2 and 
MST1/2 silencing was also confirmed in another cell line 
(MDA-MB-157) (Figure 5b). 
To address whether YAP serves as a mediator of 
HMGA1- and CCNE2-induced cell migration, we used 
a constitutively active form of YAP carrying serine-to-
alanine substitutions at the primary YAP phosphorylation 
sites (YAP-5SA) [22], including the LATS1/2-targeted 
sites Ser127 and Ser381. The constitutive expression 
of YAP-5SA was sufficient to counteract the effect of 
HMGA1 and CCNE2 silencing on MDA-MB-231 cell 
migration (Figure 5c and Supplementary Figure S5c). 
We then assessed whether LATS1/2 and MST1/2 
kinases were responsible for the YAP-mediated HMGA1 
and CCNE2 effect on cell migration. Silencing of 
LATS1/2 and MST1/2 rescued almost completely the 
effect of HMGA1 and CCNE2 depletion on cell motility 
(Figure 5d). These results therefore demonstrate that the 
activity of HMGA1 and CCNE2 is largely dependent on 
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Figure 3: CCNE2 silencing impaired the migration and invasion of basal-like breast cancer cells. a. Left, representative 
images of a wound-healing assay in which MDA-MB-231 and MDA-MB-157 cells were transfected with control siRNA (siCTRL) or two 
different siRNAs against CCNE2 mRNA (siCCNE2a or siCCNE2b) are shown. Confluent cell cultures were scratched, and wound closure 
was analyzed after 7 h with respect to time zero. Right, quantification of the wound-healing assay is presented as the means of the percentage 
of wound closure relative to the control±SD (n > 3). A representative Western blot of CCNE2 silencing in each cell line is shown. ß-actin 
was used as a loading control. b. Left, a representative transwell migration assay performed on MDA-MB-231 and MDA-MB-157 cells 
transfected with siCTRL or siCCNE2b is shown. Right, quantification of the transwell migration assay. c. The transwell invasion assay 
using the same cell lines used in b. Left, representative images of cells that migrated across the porous membrane that were stained with 
crystal violet. Right, quantification of the transwell assay. Below, a representative Western blot of CCNE2 silencing is shown. ß-actin was 
used as loading control. The data in b and c are presented as the mean of the percentage of the number of cells relative to the control±SD 
(n > 3). See Supplementary Figure S3 for transwell experiments using siCCNE2a. d. Analysis of a wound-healing assay in MDA-MB-231 
cells co-transfected with siCTRL or siHMGA1 and a vector expressing HA-CCNE2. The empty vector (-) was used as a negative control. 
The data are presented as the means of the percentage of wound closure relative to the control±SD (n = 4). Right, a representative Western 
blot analysis of the cell lysates is presented. ß-actin was used as a loading control. ***P < 0.001; two-tailed Student’s t-test.
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the core kinases of the Hippo pathway. 
CDK inhibitors regulate the nuclear localization 
of YAP and cell migration
We demonstrated that CCNE2 and HMGA1 
intercept the Hippo pathway by regulating YAP 
phosphorylation and nuclear localization. Because the 
functions of CCNE2 are predominantly dependent on 
CDK2 [26], we evaluated whether CDK2 depletion 
altered YAP localization and cell motility. Figure 6a and 
b show that following CDK2 silencing both cell motility 
and YAP nuclear localization are severely impaired. 
Thus, to test whether CDK inhibitors could be exploited 
as potential inhibitors of YAP activity, we performed a 
screen using a panel of CDK inhibitors and assessed YAP 
localization in MDA-MB-231 cells. Strikingly, most of 
the tested compounds affected YAP nuclear localization 
(Figure 6c and Supplementary Figure S6a). The three 
most effective inhibitors (AZD5438, JNJ7706621 and 
PHA793887) were also tested in another breast cancer cell 
line, MDA-MB-157, obtaining similar results (Figure 6d 
and Supplementary Figure S6a). Then, we analyzed the 
phosphorylation status of YAP at Ser127 after treatment of 
MDA-MB-231 with the three most effective compounds 
and found an increase in YAP phosphorylation at Ser127 
concomitant with the cytoplasmic translocation of YAP 
(Figure 6e). Consistently all three inhibitors were able 
to down regulate the expression of the two YAP target 
genes CTFG and CYR61 that we showed to be affected 
by HMGA1 and CCNE2 silencing (Figure 6f). Next, we 
examined whether CDK inhibitors alter the migratory 
capacity of MDA-MB-231 cells and whether this function 
is associated with the cytoplasmic translocalization of 
YAP. All three inhibitors significantly impaired cell 
migration without appreciably affecting cell proliferation 
at the concentration and time points evaluated (Figure 
6g and 6h and Supplementary Figure S6b). Notably, 
this effect was specifically mediated by YAP; in fact, the 
expression of the mutant YAP-5SA rescued cell migration, 
albeit at different levels for the three inhibitors (Figure 6g 
and 6h and Supplementary Figure S7a and b).
Figure 4: HMGA1 and CCNE2 affect YAP localization and activity. a. The boxplot shows the YAP protein phosphorylation 
level in breast cancer samples. The samples were stratified based on the expression level of CCNE2. b. Representative immunofluorescence 
images of YAP in MDA-MB-231 cells after HMGA1 and CCNE2 silencing are shown. Representative cells are indicated by arrowheads 
with abbreviations (Nuc, primarily nuclear; Cyt, primarily cytoplasmic; N/C, diffuse in the nucleus and the cytoplasm). Images were 
taken at X 60 magnification. Right, the ratio of percentage of cells with nuclear YAP treated with siCCNE2b and siHMGA1 compared 
with siCTRL. The data are presented as the mean±SD (n = 3). c. Western blot analysis of total YAP and YAP phosphorylated at Ser127 
(YAP-S127) in protein lysates of MDA-MB-231 cells transfected with siCTRL or siHMGA1 and siCCNE2b (n ≥ 5). d. Real time RT-PCR 
analysis of YAP target genes (CTGF, BIRC5, CYR61) in MDA-MB-231 cells after HMGA1 and CCNE2 silencing. GAPDH was used for 
normalization. The data are presented as the mean±SEM (n = 4). e. Contingency table frequencies of breast cancer samples (TCGA dataset) 
classified as expressing high or low levels of YAP/TAZ profile genes or displaying high or low HMGA1 and CCNE2 expression levels. *P 
< 0.05, **P < 0.01, ***P < 0.001; two-tailed Student’s t-test.
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DISCUSSION
We recently showed that HMGA1 promotes 
metastatic processes in basal-like breast cancer cells by 
regulating the EMT and stemness via the activation of a 
specific gene signature [5]. Among those genes, we found 
that CCNE2 acts downstream of HMGA1 to mediate 
breast cancer metastasis. A growing body of evidence 
indicates that CCNE2 is involved in breast cancer cell 
migration [27-29]. Indeed, CCNE2 is a component of 
three prognostic gene expression signatures that predict 
shorter metastasis-free survival [14-16]. Here, we show 
that depletion of CCNE2 strongly impairs the migration 
and invasion of breast cancer cells without significantly 
altering their proliferation. In recent years, it has become 
evident that cyclins and cyclin-dependent proteins 
play cell cycle-independent roles [27, 30-32]. Cyclin 
D1 promotes cell migration by regulating the RhoA-
ROCK pathway [33], that can in turn regulate the Hippo 
pathway [34-36]. Intriguingly, cyclin D1 is regulated by 
HMGA1 [37]. Therefore, our study extends the current 
understanding of the alternative roles of cyclins in cell 
migration, identifying CCNE2 as a novel mediator of the 
migration of breast cancer cells and suggesting a wider 
role of cyclins in regulating the Hippo pathway.
HMGA1 is widely involved in tumorigenesis due 
to its ability to interact with transcription factors and 
to modulate chromatin plasticity. Via these properties, 
HMGA1 is considered a key hub for several oncogenic 
pathways, such as the Wnt/ß-catenin and Notch pathways 
[5, 38] and Ras/ERK signaling [39]. In this study, we 
provide the first evidence that HMGA1 regulates the 
Hippo pathway via CCNE2, which ultimately modulates 
the activity of YAP. We demonstrate that HMGA1 is able 
to bind in vivo to CCNE2 promoter and activate CCNE2 
transcription. The promoter region of CCNE2 was shown 
to contain in vivo binding sites for and to be activated by 
E2F1 [40, 41]. Because it was demonstrated that HMGA1, 
by binding to Rb, was able to activate E2F target genes 
[42, 43] it is likely that this mechanism could be involved 
in the regulation of CCNE2 transcription as well. In 
addition, we provide evidence that HMGA1 can bind to 
Figure 5: HMGA1 and CCNE2 regulate YAP localization in a MST1/2 and LATS1/2 kinase-dependent manner in 
breast cancer cells. a. Immunofluorescence images of YAP in MDA-MB-231 cells, indicating the effect of LATS1/2 and MST1/2 
silencing on cells in which HMGA1 and CCNE2 were depleted. In the graph, the ratio of nuclear YAP relative to siCTRL±SD is presented 
(n = 3). Images were taken at X 40 magnification. b. The same experiment presented in a. performed in MDA-MB-157 cells. c. Wound-
healing assay using MDA-MB-231 cells stably infected with pBABE-FLAG (FLAG) or pBABE-FLAG-YAP-5SA (FLAG-5SA) after 
transfection with siCTRL, siCCNE2b or siHMGA1 for 72 h. The data are presented as the means of the percentage of wound closure 
relative to each control (siCTRL)±SD (n = 3). See Supplementary Figure S5c for Western blot analysis. d. Wound-healing assay using 
MDA-MB-231 cells treated as in panel a. *P < 0.05, **P < 0.01, ***P < 0.001, NS = not significant; two-tailed Student’s t-test.
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two AT-rich regions, AT-RR1 and AT-RR2, upstream the 
CCNE2 promoter, one of which, AT-RR2, is a potential 
S/MAR. HMGA1 is a nuclear architectural factor that 
can organize local chromatin structures regulating gene 
expression by binding to long AT-rich stretch and to S/
MAR (4, 44, 45). Therefore it is possible that AT-RR1 
and AT-RR2 distal elements could regulate CCNE2 
transcription by physically interacting with the CCNE2 
promoter through HMGA1-mediated chromatin looping. 
We found that inhibition of HMGA1 and CCNE2 
induced YAP inactivation by promoting its cytoplasmic 
localization, and we showed that this effect is mediated 
by MST1/2 and LATS1/2, the core kinases of the Hippo 
pathway. To examine the relevance of the HMGA1- and 
CCNE2-mediated inhibition of YAP to the induction 
of cell migration, we used a constitutively active form 
of YAP (YAP-5SA). This mutant rescued the effect of 
HMGA1 and CCNE2 silencing on cell migration. These 
results suggest that the HMGA1-CCNE2-YAP axis acts 
via the Hippo pathway to modulate oncogenic properties, 
such as cell migration. The mechanism by which HMGA1 
modulates the activity of MST1/2 and LATS1/2 remains 
an open question that merits further investigation. 
These results might also be relevant to 
developmental studies. Several reports have indicated 
that HMGA1 and the highly related HMGA2 protein are 
implicated in regulating body size. Indeed, knockout of 
Hmga2 is responsible for the pygmy phenotype in mice 
[46], and Hmga1 and Hmga2 double knockout results 
in a super pygmy phenotype [43]. The Hippo pathway 
constitutes an intrinsic regulator of organ size, as well. 
Inactivation of this cascade causes excess nuclear 
accumulation of YAP/TAZ, leading to organ overgrowth 
[21, 47, 48]. Thus, we propose that these two pathways 
might cooperate during development, as well as during 
cancer.
The Hippo signaling pathway is frequently 
deregulated in many different cancers, including breast 
cancer [25]. Therefore, pharmacological inhibition of 
YAP/TAZ activity may represent an effective anticancer 
strategy. However, to date, few small molecule inhibitors 
that target the Hippo pathway have been discovered. 
Figure 6: CDKs affect YAP localization and the motility of breast cancer cells. a. Wound-healing assay in MDA-MB-231 
cells transfected with control siRNA (siCTRL) or a pool of siRNAs against CDK2, data is presented as the means of the percentage of 
wound closure relative to the control±SD (n > 3). b. Immunofluorescence analysis of YAP localization in MDA-MB-231 treated as in a. 
Data is presented as percentage of cells with nuclear YAP in each condition. c. Results of the CDK inhibitor library screening evaluating 
YAP localization. MDA-MB-231 cells were treated for 24 h with 1 mM of inhibitor, except for SNS-032 and DINACICLIB, which were 
applied at 0.1 mM. The data are presented as the means of percentage of cells with nuclear YAP±range between replicates (n = 2). See 
Supplementary Figure S6a for representative images. d. Immunofluorescence analysis of YAP localization in MDA-MB-157 treated with 
the most effective CDK inhibitors (AZD5438, JNJ7706621 or PHA793887). Data is presented as percentage of cells with nuclear YAP 
in each condition (n = 3). See Supplementary Figure S6a for representative images. e. Western blot of total YAP and phosphorylated 
YAP at Ser127 (YAP-S127) in protein lysates of MDA-MB-231 cells treated with CDK inhibitors (n = 3). f. Real time RT-PCR analysis 
of YAP target genes (CTGF and CYR61) in MDA-MB-231 cells treated with CDK inhibitors. GAPDH was used for normalization. The 
data are presented as the mean±SD (n = 3). g. and h. Wound-healing assay (g) and transwell migration assay (h) using MDA-MB-231 
cells stably infected with pBABE-FLAG (FLAG) or pBABE-FLAG-YAP-5SA (FLAG-5SA) after the treatment with CDK inhibitors. See 
Supplementary Figure S7a and b for representative images of wound-healing and transwell respectively. Experiments presented in panel 
d-h were performed in cells treated with AZD5438, JNJ7706621 or PHA793887. The data are presented as the means of the percentage 
relative to each control (DMSO)±SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001; two-tailed Student’s t-test.
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Among these inhibitors, statins have very recently been 
shown to display the potential to target the malignant 
effects of YAP/TAZ in cancer cells [49, 50]. Because 
inhibition of a single CDK can be overcome by the 
compensatory activity of other CDKs [51], we evaluated 
the effects of CDK pan-inhibitors on YAP localization and 
showed that several CDK inhibitors effectively inhibit 
YAP, decreasing its nuclear localization and activity 
impairing cell migration. CDK inhibitors are considered 
attractive compounds for blocking CDK activities, 
primarily consisting of regulation of the cell cycle and 
cell proliferation [51]. An intensive search is on-going 
for possible therapeutic applications of CDK inhibitors; 
in fact, several CDK inhibitors are under investigation in 
clinical trials. Interestingly, their potential to inhibit tumor 
growth in mice has been demonstrated [52]. Moreover, we 
found that CDK inhibitors decrease the migratory capacity 
of breast cancer cells. Therefore, we suggest investigating 
the efficacy of these compounds for their ability to reduce 
metastasis in vivo. 
In conclusion, we demonstrate that the novel 
HMGA1-CCNE2 axis regulates cell migration by 
intercepting the Hippo pathway and, ultimately, by 
modulating YAP activity. Moreover, we propose the use 
of CDK inhibitors to target the Hippo pathway.
MATERIALS AND METHODS
Cell culture and treatments
MDA-MB-231, MDA-MB-157 and HEK-
293 cell lines were cultured in DMEM containing 
10% tetracycline-free FBS, 2 mM L-glutamine, 100 
U/ml penicillin and 100 μg/ml streptomycin. For 
transfection of siRNA, all cell lines were transfected with 
LipofectamineTM RNAiMAX reagent (Invitrogen) for 72 
h. The siRNAs against HMGA1 (siA1_1 and siA1_3, 
referred to as siHMGA1 throughout the text) [5] and the 
siRNA against CCNE2 (siCCNEa) were used previously 
[53]. siCCNE2b -5’ GAAAGCCUCAGGUUUGGAG 
3’- was designed using an Invitrogen tool to target exon 
10; siLATS1/2 was used previously [49]; for MST1/2 
silencing we used a pool of siRNAs composed by siMST1 
-5’ GCAGGUCAACUUACAGAUA 3’- and siMST2 -5’ 
CCACAAGUACAAAGACCAU 3’-; for CDK2 silencing 
we used a pool of siRNAs composed by siCDK2_1 -5’ 
GCUUGGCCUUGGGCUAUUU 3’- and siCDK2_2 
-5’ GCCUUCCUACACGUUAGAU 3’-. siMST1/2 and 
siCDK2s were designed using an Invitrogen tool. Plasmid 
transfections were performed using either FuGENEHD 
(Promega) or Lipofectamine 3000 (Invitrogen) or standard 
Calcium Phosphate method. For pcDNA3HA-CCNE2 
plasmid construction, the CCNE2 coding sequence was 
amplified from reverse-transcribed total RNA of MDA-
MB-231 cells using the following primers: forward 
-5’ TTAACGGAATTCATGTCAAGACGAAGTAGC 
3’- and reverse -5’ 
TCTCCTCGAGTTATTAGTGTTTTCCTGGTGG 
3’- and the resulting fragment was cloned into EcoRI 
and XhoI restriction sites of pcDNA3HA. The plasmid 
DNA was checked by sequencing. For functional-
rescue experiments, the cells were initially transfected 
with siRNA; 24 h later, the cells were transfected with 
plasmid pcDNA3HA or pcDNA3HA-CCNE2 using 
FuGENEHD (Promega), experiments were done 48 h 
after. For overexpression experiment, MDA-MB-231 
cells were transfected with plasmids pEGFP-N1 or 
pEGFP-N1 HMGA1a, that was a kind gift from Prof. 
G. Giannini, using Lipofectamine 3000 (Invitrogen), 
experiment was done 30 h after transfection. For 
experiments using YAP-5SA, MDA-MB-231 cells were 
initially transfected with pBABE-FLAG and pBABE-
FLAG-YAP-5SA [49], selected using puromycin and then 
silenced for 72 h using siCTRL, siA1_3 or siCCNE2b. For 
LATS1/2 and MST1/2 silencing, the cells were initially 
transfected with siLATS1/2 or siMST1/2; after 24 h, the 
cells were transfected with siHMGA1 and siCCNE2b 
for 48 h. For CDK inhibitor screening, cells were 
treated with PD03329911, SNS-032, ROSCOVITINE, 
PHA793887, AT7519, BS181HCl, BMS265246, 
AZD5438, FLAVOPIRIDOL, PHA767491, PHA848125, 
DINACICLIB or JNJ7706621 for 24 h (Sellekchem). 
These inhibitors were applied at 1 µM, except for SNS-
032 and DINACICLIB, which were applied at 0.1 µM. 
Immunoblotting
The cells were washed in chilled PBS and lysed 
using SDS sample buffer [62.5 mM Tris, pH 6.8; 2% 
SDS; 10% glycerol; 50 mM DTT; 1 mM Na3Vo4; 5 mM 
NaF; and mammalian protease inhibitor cocktail (PIC) 
(Sigma)]. The lysates were separated via SDS-PAGE prior 
to transfer to nitrocellulose membranes (GE-Healthcare). 
Western blot analyses were performed according to 
standard procedures using the following antibodies: anti-
CCNE2 (Abcam); anti-ß-actin (Sigma); anti-HMGA1 
[5]; anti-YAP (Santa Cruz); anti-P127-YAP (Novus 
Biological); and anti-FLAG (Sigma).
Immunostaining
The cells were grown at low density on glass slides 
and fixed with 4% PFA. After permeabilization with 0.3% 
Triton/PBS and saturation in 0.5% BSA/PBS, the cells 
were incubated in the anti-YAP primary antibody (Santa 
Cruz) diluted in PBS containing 0.5% BSA and 0.01% 
Triton. The anti-mouse Alexa 488 secondary antibody 
(Invitrogen) was applied. Then, the cells were stained with 
Hoechst to detect the nuclei. The images were visualized 
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using a Nikon Eclipse e800 microscope and acquired 
using Nikon ACT-1 software.
Migration and invasion assays
For the wound-healing assays, the cells were 
cultured to confluence on 35-mm plates. Then, the cells 
were scraped using a 200-μl tip, and wound closure 
was monitored for 7 h. Images of the same area were 
captured for each plate, and wound closure was analyzed 
using ImageJ software. For the transwell migration and 
invasion assays, 24-well PET inserts were used (8.0-mm 
pore size, Falcon) without or with Matrigel-coated filters 
for invasion; 40,000 and 100,000 cells were seeded, 
respectively. The migrated and invaded cells were fixed 
after 22 h and 24 h, respectively, in 4% PFA and were 
stained with 0.5% crystal violet (Sigma).
MTS cell growth analysis
First, 5,000 cells were seeded in 96-well dishes. 
Every 24 h, cell growth was measured via a CellTiter 
96® AQueous One Solution Cell Proliferation Assay 
(Promega) according to the manufacturer’s instructions. 
At each time point, the medium in each well was replaced 
with a solution composed of 100 µl of PBS containing 4.5 
g/L glucose (Sigma) and 20 µl of CellTiter 96® AQueous 
One Solution.
Promoter analysis
Putative MARs were mapped using MAR-Wiz 
(http://genomecluster.secs.oakland.edu/cgi-bin/mar-
upload.cgi), with default parameters. Putative HMGA1 
binding site were obtained using MatInspector tool 
(http://www.genomatix.de/cgi-bin//eldorado/main.pl). The 
analyzed sequence is from +226 to – 11430 of CCNE2 
gene. 
Luciferase assay
HEK-293 cells were plated at density of 350,000 
cells per 35-mm-diameter culture dish and processed 46.5 
h after standard calcium phosphate transfection. Cells 
were transfected with 500 ng of the reporter construct, 
1 μg of pcDNA3HA or pcDNA3HA-HMGA1a, and 50 
ng of pRL-CMV Renilla luciferase expression vector 
(Promega) to normalize for transfection efficiencies. 
Reporter constructs are: pGL4-CCNE2 (kindly given 
by Jay A. Nelson laboratory) and pGL4-ΔCCNE2 that 
was obtained by amplifying a fragment of 223nt from 
pGL4-CCNE2 using the following primers: forward 
AATCTCGAGGTGCGGGGCGGGAC and reverse 
ACCCAAGCTTACGGAACGCGGGAACCCA and 
cloned in HindIII and XhoI restriction sites of pGL4.11 
(Promega). The assays were performed with dual-
luciferase reporter assay system (Promega) according to 
the manufacturer’s instruction.
Chromatin immunoprecipitation
MDA-MB-231 cells were cross-linked in culture 
medium with 1 % formaldehyde for 10 min, neutralized 
using 125 mM glycine in PBS for 5 min and washed in 
PBS. Nuclei were obtained by hypotonic buffer (5 mM 
Pipes pH 6.8, 85 mM KCl, 0.5 % NP-40 and protease 
inhibitors) and centrifugation. The nuclei pellet was 
resuspended in RIPA 100mM buffer (20 mM Tris-
HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP-
40, 0.5% Na-Deoxycholate, 0.1% SDS supplemented 
with protease inhibitors). Chromatin was sonicated to 
500-800 bp average fragment size and precleared for 1 
h at 4°C with protein A/G PLUS-Agarose (Santa Cruz 
Biotechnologies). Agarose was removed by centrifugation 
and an aliquot of supernatant was taken as input. 
Chromatin was immunoprecipitated overnight at 4°C 
with anti-HMGA1 polyclonal antibody. As a negative 
control for immunoprecipitation, IgGs purified from 
rabbit serum were used (Abcam). DNA protein complexes 
were recovered with protein A/G PLUSAgarose and 
washed sequentially with RIPA 100 mM buffer, RIPA 
250 mM buffer (20 mM Tris-HCl pH 7.5, 250 mM NaCl, 
1 mM EDTA, 0.5% NP-40, 0.5% Na-Deoxycholate and 
0.1% SDS), LiCl solution (10 mM Tris-HCl pH 8.0, 1 
mM EDTA, 250 mM LiCl, 0.5% NP-40 and 0.5% Na-
Deoxycholate) and TE. To reverse cross-linking, samples 
were incubataed overnight at 65°C and after that RNase 
A (35 ng/μl) and proteinase K (90ng/μl) treatment was 
performed for 2 h at 55°C (0.2%, SDS, 35mM Tris HCl 
pH6.5, 8.8 mM EDTA pH 8). In parallel, input was treated 
in the same way. After phenol/chloroform extraction and 
ethanol precipitation samples were resuspended in H2O. 
Coimmunoprecipitated DNA was analyzed by Real Time 
PCR. Promoter occupancy was calculated as percent 
of chromatin input immunoprecipitated using the 2-ΔCt 
method. Primer sequences are available on request.
Gene expression analysis
Total RNA was extracted using TRIzol reagent 
(Invitrogen), subjected to DNase-I (Invitrogen) treatment 
and subsequently purified using phenol-chloroform. 
For quantitative RT-PCR, mRNA was transcribed using 
Superscript III (Invitrogen). Quantitative PCR was 
performed using SYBR Green PCR master mix (Applied 
Biosystems) and a 7500 Real-Time PCR System (Applied 
Biosystems). The primer sequences used are available 
upon request.
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Analysis of DNA/protein content (PI/FITC 
staining)
For each sample, the cells (106) were fixed in 70% 
ethanol, pre-hydrated in PBS for 6 minutes, washed twice 
with PBS, and allowed to balance in PBS for 1 h. The 
cells were stained overnight with 500 µl of a PBS-based 
solution containing 10 μg of PI and 0.25 ng of FITC (all 
from Sigma). All flow cytometric measurements were 
performed using a CYTOMICSTM FC500 (Beckman 
Coulter Inc. Fullerton, CA, USA) equipped with an 
Argon laser (488 nm, 5 mV) and configured according to 
standard parameters for green-filtered (525 nm, FL1) and 
red-filtered (610 nm, FL3) fluorescent detection (http://
dsv.units.it/Dipartimento/fcs_dsv). After acquisition of at 
least 10,000 events per run, the data, which were stored 
as list mode files, were analyzed using FCS Express V3 
software; alternatively, the saved FL3 histograms were 
subjected to cell cycle analysis, which was performed 
using MultiCycle® software.
Breast cancer gene expression data
Data processing was performed using several 
BioConductor packages (survival, affy and limma; see 
http://www.bioconductor.org/) in the R Computing 
Environment version 3.0.2 (http://www.r-project.org/).
Breast cancer meta-dataset
Several published gene expression datasets (breast 
cancer meta-dataset) were collected from the gene 
expression omnibus (GEO) public gene expression 
database (GSE1456, GSE4922, GSE5327, GSE6532, 
GSE7390, GSE11121, GSE12093, GSE2603, GSE16446, 
GSE19615, GSE20685 and GSE21653). The data were 
normalized in the R/Bioconductor environment using the 
RMA normalization method (affy package), generating a 
breast cancer meta-dataset. Gene annotation was obtained 
from brainarray custom CDF metadata packages, and the 
probe sets were converted to Entrez Gene Id and Symbol 
Id. Each dataset was analyzed separately to avoid platform 
and signal merging issues, and only the results were 
combined.
Breast cancer TCGA dataset
Gene expression data for the breast cancer samples 
(TCGA data set) were obtained from the Memorial 
Sloan Kettering Cancer Genomics Portal (http://www.
cbioportal.org/public-portal; last accessed on 6 July 2014). 
Beginning with the Breast Invasive Carcinoma data set 
(TCGA, Provisional, n = 1037), each patient was classified 
as expressing high or low levels of YAP/TAZ profile 
genes and of the HMGA1 or CCNE2 genes. The genes 
comprising the YAP/TAZ signature are as follows: KRT34; 
STXBP6; OLR1; THBS1; INHBA; CTGF; SERTAD4; 
ANKRD1; HSD3B1; ORC1; CENPM; DAW1; ITGB2; 
IGFBP3; TGM2; ADAMTS1; BDNF; TMEM171; 
SERPINE2; PTGS2; CCDC18; PLCB4; DEPDC1B; 
ZBED2; MATN3; CCNA2; TBXA2R; SERPINE1; 
SLIT2; BCAR4; ZWINT; RAD51; DIAPH3; MCM10; 
NAV3; SKA1; SHCBP1; RAD51AP1; DDAH1; RIMS2; 
RRM2; CDC6; PRR16; DAB2; PLK4; ASF1B; KIF14; 
FMN2; CDC25C; and GINS2. Statistical independence 
between the different molecular conditions was calculated 
using Pearson’s Chi-squared contingency table tests in the 
R/Bioconductor environment. 
Survival analysis
Kaplan–Meier survival curves of distant metastasis-
free survival (DMFS) of breast cancer patients were 
classified according to the expression of CCNE2 or 
HMGA1 using the survival package. To evaluate the 
correlation between the CCNE2 expression levels and 
clinical breast cancer data, we also confirmed our analysis 
using the gene expression-based Outcome for Breast 
Cancer web tool (GOBO) [54].
For the single regression Cox gene analysis, we 
used only a subset of the meta-dataset to compare the 
gene expression data to the DMFS duration. In particular, 
we used only the Affymetrics HGU133A platform data to 
avoid the platform type as a confounding variable in the 
models.
Protein phosphorylation analysis
The protein phosphorylation data were obtained 
from the TCGA breast invasive carcinoma dataset via 
cBioPortal (http://www.cbioportal.org/public-portal/index.
do). In particular, using CCNE2 as the gene of interest 
in the input form, we selected the proteins displaying 
differential phosphorylation according to the RPPA data.
Statistical analysis
The data were analyzed via two-tailed Student’s t 
tests, and the results were considered significant at a P < 
0.05. The results are presented as the mean.
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